These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 20172961)

  • 21. Steroid sulfatase inhibition success and limitation in breast cancer clinical assays: An underlying mechanism.
    Sang X; Han H; Poirier D; Lin SX
    J Steroid Biochem Mol Biol; 2018 Oct; 183():80-93. PubMed ID: 29803725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pseudo-symmetry of C19 steroids, alternative binding orientations, and multispecificity in human estrogenic 17beta-hydroxysteroid dehydrogenase.
    Gangloff A; Shi R; Nahoum V; Lin SX
    FASEB J; 2003 Feb; 17(2):274-6. PubMed ID: 12490543
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Downregulation of Dihydrotestosterone and Estradiol Levels by HEXIM1.
    Mozar F; Sharma V; Gorityala S; Albert JM; Xu Y; Montano MM
    Endocrinology; 2022 Jan; 163(1):. PubMed ID: 34864989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new nonestrogenic steroidal inhibitor of 17β-hydroxysteroid dehydrogenase type I blocks the estrogen-dependent breast cancer tumor growth induced by estrone.
    Ayan D; Maltais R; Roy J; Poirier D
    Mol Cancer Ther; 2012 Oct; 11(10):2096-104. PubMed ID: 22914440
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insight into the mode of action and selectivity of PBRM, a covalent steroidal inhibitor of 17β-hydroxysteroid dehydrogenase type 1.
    Trottier A; Maltais R; Ayan D; Barbeau X; Roy J; Perreault M; Poulin R; Lagüe P; Poirier D
    Biochem Pharmacol; 2017 Nov; 144():149-161. PubMed ID: 28800957
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients.
    Chanplakorn N; Chanplakorn P; Suzuki T; Ono K; Chan MS; Miki Y; Saji S; Ueno T; Toi M; Sasano H
    Breast Cancer Res Treat; 2010 Apr; 120(3):639-48. PubMed ID: 20151319
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis of 16β-derivatives of 3-(2-bromoethyl)-estra-1,3,5(10)-trien-17β-ol as inhibitors of 17β-HSD1 and/or steroid sulfatase for the treatment of estrogen-dependent diseases.
    Lespérance M; Roy J; Djiemeny Ngueta A; Maltais R; Poirier D
    Steroids; 2021 Aug; 172():108856. PubMed ID: 33945801
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and biological evaluation of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-one core.
    Lilienkampf A; Karkola S; Alho-Richmond S; Koskimies P; Johansson N; Huhtinen K; Vihko K; Wähälä K
    J Med Chem; 2009 Nov; 52(21):6660-71. PubMed ID: 19824648
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural basis for the selective inhibition of human 3beta-hydroxysteroid dehydrogenase 1 in human breast tumor MCF-7 cells.
    Thomas JL; Bucholtz KM; Sun J; Mack VL; Kacsoh B
    Mol Cell Endocrinol; 2009 Mar; 301(1-2):174-82. PubMed ID: 18955108
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A challenge for medicinal chemistry by the 17β-hydroxysteroid dehydrogenase superfamily: an integrated biological function and inhibition study.
    Lin SX; Poirier D; Adamski J
    Curr Top Med Chem; 2013; 13(10):1164-71. PubMed ID: 23647539
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current knowledge of the multifunctional 17β-hydroxysteroid dehydrogenase type 1 (HSD17B1).
    He W; Gauri M; Li T; Wang R; Lin SX
    Gene; 2016 Aug; 588(1):54-61. PubMed ID: 27102893
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Crystallization and preliminary crystal structure of the complex of 17beta-hydroxysteroid dehydrogenase with a dual-site inhibitor.
    Zhu DW; Campbell R; Labrie F; Lin SX
    J Steroid Biochem Mol Biol; 1999; 70(4-6):229-35. PubMed ID: 10622412
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blocking 17β-hydroxysteroid dehydrogenase type 1 in endometrial cancer: a potential novel endocrine therapeutic approach.
    Konings GF; Cornel KM; Xanthoulea S; Delvoux B; Skowron MA; Kooreman L; Koskimies P; Krakstad C; Salvesen HB; van Kuijk K; Schrooders YJ; Vooijs M; Groot AJ; Bongers MY; Kruitwagen RF; ; Romano A
    J Pathol; 2018 Feb; 244(2):203-214. PubMed ID: 29144553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overexpression of 17β-hydroxysteroid dehydrogenase type 1 increases the exposure of endometrial cancer to 17β-estradiol.
    Cornel KM; Kruitwagen RF; Delvoux B; Visconti L; Van de Vijver KK; Day JM; Van Gorp T; Hermans RJ; Dunselman GA; Romano A
    J Clin Endocrinol Metab; 2012 Apr; 97(4):E591-601. PubMed ID: 22362820
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Receptor isoform and ligand-specific modulation of dihydrotestosterone-induced prostate specific antigen gene expression and prostate tumor cell growth by estrogens.
    Zhu YS; Cai LQ; Huang Y; Fish J; Wang L; Zhang ZK; Imperato-McGinley JL
    J Androl; 2005; 26(4):500-8; discussion 509-10. PubMed ID: 15955889
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural basis for species specific inhibition of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1): computational study and biological validation.
    Klein T; Henn C; Negri M; Frotscher M
    PLoS One; 2011; 6(8):e22990. PubMed ID: 21857977
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estradiol suppresses tissue androgens and prostate cancer growth in castration resistant prostate cancer.
    Montgomery B; Nelson PS; Vessella R; Kalhorn T; Hess D; Corey E
    BMC Cancer; 2010 May; 10():244. PubMed ID: 20509933
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dehydroepiandrosterone and dihydrotestosterone recognition by human estrogenic 17beta-hydroxysteroid dehydrogenase. C-18/c-19 steroid discrimination and enzyme-induced strain.
    Han Q; Campbell RL; Gangloff A; Huang YW; Lin SX
    J Biol Chem; 2000 Jan; 275(2):1105-11. PubMed ID: 10625652
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bicyclic substituted hydroxyphenylmethanone type inhibitors of 17 β-hydroxysteroid dehydrogenase Type 1 (17 β-HSD1): the role of the bicyclic moiety.
    Oster A; Klein T; Henn C; Werth R; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
    ChemMedChem; 2011 Mar; 6(3):476-87. PubMed ID: 21337522
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone.
    Bellavance E; Luu-The V; Poirier D
    J Med Chem; 2009 Dec; 52(23):7488-502. PubMed ID: 19772289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.